2023 annual financial data
Edgewise Therapeutics 2023 Operating margin
Direct answer
Operating margin was Not calculable.
Operating income was -114,357,000 USD and net income was -100,163,000 USD.
Operating cash flow was -91,948,000 USD.
Get free Edgewise Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -114,357,000 USD
- Net income
- -100,163,000 USD
- Operating cash flow
- -91,948,000 USD